Synapse - Genitourinary Oncology Service

Results (96)

NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)

Meeting Abstract

Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Targeted CRISPR-Knockout (KO) screening to identify FOXF1 regulators and therapeutic strategies in gastrointestinal stromal tumor (GIST)

Meeting Abstract

Tomas, F.; Cho, W. H.; Li, D.; Callychurn, V. R.; Wang, N.; Yu, C.; Chi, P.
European Journal of Cancer (2024)

Fulltext@MSK | Save

Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)

Meeting Abstract

Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations

Meeting Abstract

Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)

Meeting Abstract

Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

Journal Article

Liu, S. Y.; Erazo, T.; Jee, J.; Arfe, A.; Gupta, A.; Pike, L. R. G.; Santini, F. C.; Daly, B.; Schoenfeld, A.; Eichholz, J.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

Journal Article

Carril-Ajuria, L.; Lavaud, P.; Dalban, C.; Negrier, S.; Gravis, G.; Motzer, R. J.; Chevreau, C.; Tannir, N. M.; Oudard, S.; McDermott, D. F.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

Journal Article

Bührer, E.; D'Haese, D.; Daugaard, G.; de Wit, R.; Albany, C.; Tryakin, A.; Fizazi, K.; Stahl, O.; Gietema, J. A.; De Giorgi, U.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients

Journal Article

Brahmer, J. R.; Long, G. V.; Hamid, O.; Garon, E. B.; Herbst, R. S.; Andre, T.; Armand, P.; Bajorin, D.; Bellmunt, J.; Burtness, B.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Journal Article

Janku, F.; Kim, T. M.; Iyer, G.; Spreafico, A.; Elez, E.; de Jonge, M.; Yamamoto, N.; van der Wekken, A. J.; Ascierto, P. A.; Maur, M.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save